Article in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Kristin FichnaInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.
Maria Crespo-CuadradoInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.
Acsah KonuparambanCIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, 20014 Donostia/San Sebastián, Spain.
Valerio Di CarloInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.ORCID 0000-0002-5099-0685
David Esporrín-UbietoInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.ORCID 0000-0002-9858-415X
Ines Macías-TarríoInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.
Oriol Jutglar SolerInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.ORCID 0009-0001-4028-9764
Shuqin ChenInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.
María Gómez-MartínezCIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, 20014 Donostia/San Sebastián, Spain.
Anna C BakeneckerInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.
Antoni VilasecaDepartment of Urology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
Jordi LlopCIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramón 182, 20014 Donostia/San Sebastián, Spain.ORCID 0000-0002-0821-9838
Samuel SánchezInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Baldiri i Reixac 10-12, 08028 Barcelona, Spain.ORCID 0000-0001-9713-9997
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Nanoparticles are widely used in nanomedicine for controlled drug delivery and improved bioavailability. However, their effectiveness is often limited by passive diffusion, especially in confined, fluid-filled environments like the bladder, where rapid drug clearance and uneven distribution reduce therapeutic impact. These challenges contribute to high recurrence in bladder cancer despite intravesical chemotherapy. To address this limitation, we present urease-powered nanomotors (NM) based on mesoporous silica nanoparticles loaded with Mitomycin C (MMC), the standard chemotherapeutic for nonmuscleinvasive bladder cancer. These NM useurea present in urine to induce motion and drug dispersion.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Nanomotor-Assisted Intravesical Chemotherapy for Bladder Tumor Reduction and Suppression of Early Tumor Regrowth. · full record | OpenQuestion